Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

153.24 +0.94 (+0.62%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2026 Add to My Watchlist

Price and Volume

Volume	123,986
Open	152.23
Bid (Size)	138.21 (100)
Ask (Size)	156.95 (100)
Prev. Close	152.30
Today's Range	150.40 - 155.88
52wk Range	59.05 - 200.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗

July 09, 2026

Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy...

Via MarketBeat

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

July 06, 2026

From Belite Bio, Inc

Via GlobeNewswire

Performance

YTD	-3.8%	-3.8%
1 Month	+8.4%	+8.4%
3 Month	-15.4%	-15.4%
6 Month	-6.6%	-6.6%
1 Year	+138.8%	+138.8%

More News

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

July 06, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026 ↗

March 02, 2026

Via Chartmill

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

June 12, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 02, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Q1 Earnings Call Highlights ↗

May 20, 2026

Via MarketBeat

Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗

May 20, 2026

Via The Motley Fool

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

May 20, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

May 18, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

May 15, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

May 13, 2026

From Belite Bio, Inc

Via GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

April 29, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

April 27, 2026

From Belite Bio, Inc

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

April 23, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio to Participate in Four Upcoming Investor Conferences

April 23, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th

April 22, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

April 21, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

March 31, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio (BLTE) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Via The Motley Fool

Belite Bio to Participate in the Leerink Global Healthcare Conference

March 02, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 02, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

January 29, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

January 27, 2026

From Belite Bio, Inc

Via GlobeNewswire

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?

Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.

What exchange does Belite Bio, Inc - American Depositary Shares trade on?

Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?

The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market

What is the current price of Belite Bio, Inc - American Depositary Shares?

The current price of Belite Bio, Inc - American Depositary Shares is 153.24

When was Belite Bio, Inc - American Depositary Shares last traded?

The last trade of Belite Bio, Inc - American Depositary Shares was at 07/09/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.